Wed, Oct 1, 2014, 9:21 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

dctrig 42 posts  |  Last Activity: Sep 30, 2014 4:15 PM Member since: Jan 26, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • There were no significant complications or untoward
    Conclusion: Reversible vagal nerve blocking with the implantable
    Maestro Rechargeable System results in medically
    meaningful weight loss as well as improvement in diabetes
    control in obese subjects with T2DM. Most significantly, the
    benefits are sustainable to at least 36 months after implant

  • This is a rare instance where "Johnny Comes Latelys" get a super low buyin price. Notice as the stock is beaten down Barrons still shows moderate accumulation. Many small biotechs are being beaten down prior to another upward trajectory.

  • The two authors of the AMA opinion were unbelievably biased and misleading in their response. One expects this of Seeking Alpha writers, but not so-called healthcare professionals.

  • Reply to

    Final shakedown

    by pharmaapproved Sep 19, 2014 3:34 PM
    dctrig dctrig Sep 19, 2014 8:06 PM Flag

    Barrons showed nice accumulation in ETRM on Friday: 1.68 positive uptick ratio and $138,836 positive net money flow into the stock.

  • Reply to

    3 Bidders: JNJ, GSK and Medtronic

    by adeiflig Aug 20, 2014 12:20 PM
    dctrig dctrig Aug 20, 2014 4:11 PM Flag

    Wow! Trading volume today was the lowest in three months. You have to go back to 5/22 to find a lower volume day. Naturally, today's low volume enabled bears to erode the stock price, while Barrons still showed some continued accumulation.

  • Friday, 8/15, marked the seventh straight day that ETRM established a higher low: 1.25, 1.28, 1.34, 1.41, 1.42, 1.43, 1.45

  • Reply to

    FDA Approval appears unlikely.

    by platguru Aug 26, 2014 3:46 PM
    dctrig dctrig Aug 26, 2014 5:44 PM Flag

    oozhe: you are selectively picking negatives to make your case. Even uber-skeptic Alan Feuerstein is resigned to FDA approval, but hedges on future sales.

  • The European authorities have been considering ETRM's CE mark application for hypertension for a couple of years.

  • We were heading for a 1.19 or 4 cent drop, then the final NASDAQ close of 1.23 on 23,762 shares brought us even. Rarely have I seen a 4 cent spread between the official NASDAQ closing price and the last previous sale. Usually the spread is 1 or 2 cents.

  • Reply to

    ETRM Target Price $ 30 per share....

    by adeiflig Jul 10, 2014 9:21 AM
    dctrig dctrig Jul 10, 2014 10:32 AM Flag

    Ade: Your perfect world scenario for VBLOC is outlandish. Meaningful insurance reimbursement won't kick in for at least a year. VBLOC's results are not strong enough to dislodge lapband and gastric bypass, but merely to offer a less invasive alternative. In addition to the sales staff there also needs to be doctor trainers and health support professionals, none of which comes cheap. Startup expenses are high and if ETRM goes it alone it will take easily three years to achieve profitability. ETRM's best bet is to partner or sell. My target price is $7.

    Sentiment: Buy

  • Look at Spectrum's drug, approved a month ahead of their PDUFA date. The approval hurdle for medical devices with negligible cardiovascular risk is much much lower. Enteromedics and the FDA have already agreed on the post-approval five year monitoring. The complete 24-month data which the FDA now has confirms the widening gap favoring VBLOC vs. placebo.

  • Reply to

    I hope the shorts choke!

    by dh4pss Sep 11, 2014 4:17 PM
    dctrig dctrig Sep 11, 2014 4:41 PM Flag

    In court docs for various high frequency trading desks it has come out that they have an unbelievable winning trading day 9 times out of 10. One HFT desks only had one losing day in a whole year! This is 2014, not 2004, and even market makers are getting burned by algorithm trading. Today ETRM was down 6% but had 1.67 uptick ratio and NET POSITIVE money flow into the stock of $101,603. Retail investors and micro cap funds lost today but the predators had their usual winning day.

  • Reply to

    I hope the shorts choke!

    by dh4pss Sep 11, 2014 4:17 PM
    dctrig dctrig Sep 11, 2014 4:45 PM Flag

    This is why VBLOC will be approved:

    "Obesity continues to be a major public health concern," said Dr. Jean-Marc Guettier, director of the Division of Metabolism and Endocrinology Products in FDA's Center for Drug Evaluation and Research. "When used as directed in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, Contrave provides another treatment option for chronic weight management for people who are obese or are overweight and have at least one weight-related health condition."

  • Reply to

    Look at the Russell 2000 ( RUT )

    by innsbrooklad Sep 22, 2014 12:33 PM
    dctrig dctrig Sep 22, 2014 1:35 PM Flag

    I agree. Investors forget that the majority of mathematically-derived trading systems promote a herd mentality whereby a downward or upward signal produces a pile-on effect. HF trading desks are in it to make money, not correctly value stocks; in fact, most of their money is made in overvalued or undervalued stocks/options.

  • Reply to

    Institutions currently hold 31.5 %

    by siddharthkool Jul 10, 2014 1:20 PM
    dctrig dctrig Jul 10, 2014 2:21 PM Flag

    According to E-Trade 58 large block holders own 51.8%

  • Reply to

    ETRM setting itself up for BUYOUT!!!

    by adeiflig Jul 4, 2014 2:42 PM
    dctrig dctrig Jul 7, 2014 1:53 AM Flag

    rodtross: Why are you greatly exaggerating the "bonus/salary increase grab"? It amounts to approximately a modest $250,000 now and $89,000 in salary increases over a 12-month period. Today's employees expect money for a job well done and the timing was appropriate and a morale booster. ETRM's executive salaries are well in line with their peer group.

  • Reply to

    Share action before FDA decision

    by kislapmata55 Jul 2, 2014 1:56 PM
    dctrig dctrig Jul 2, 2014 2:28 PM Flag

    One can buy today at 20 cents below what director Friedman paid to add 11,800 shares to her family trust. Stock put into the majority of family trusts is kept there for long-term cap gains. Cathy spent 23 years with M & A giant Morgan Stanley and has a lot more inside info than we do.

  • Reply to

    ETRM Target Price $ 30 per share....

    by adeiflig Jul 10, 2014 9:21 AM
    dctrig dctrig Jul 10, 2014 2:27 PM Flag

    Ade, to correct you there are other potential competitors on deck per FierceMedicalDevices:
    USGI Medical, a California-based devicemaker focused on incisionless, endoscopic procedures for weight loss, reflux and advanced therapeutic endoscopy, said enrollment has been completed for a pivotal study to evaluate the company's POSE (Primary Obesity Surgery, Endolumenal) procedure.

    Last October, the FDA gave conditional investigational device exemption (IDE) approval to USGI to begin enrollment. The company said it has signed up 332 patients at 11 U.S. sites for its ESSENTIAL trial. The study will be randomized and sham-controlled. Participating patients will use USGI's g-Cath EZ Suture Anchor Delivery Catheter to place tissue anchors across folds of tissue in certain parts of the stomach in order to reduce its size and ability to stretch to accommodate a meal.

    "If the outcomes from the POSE procedure are positive and consistent with smaller trials, it could mean that tens of thousands of patients may have an incredibly compelling option to consider if they've struggled to lose weight with diet and exercise, but aren't candidates for or are not prepared to accept the risk of traditional bariatric surgery," Thomas Lavin, the lead investigator of the study, said in a statement.

    Surgeons have already performed the incisionless, outpatient procedure on more than 2,000 patients, mostly in Europe, working through the mouth. Patients return to work, bandage-free, within two to three days. In one study conducted in Spain, patients who had the procedure reported feeling full quicker and less hungry between meals, the company said. A year after the procedure, those patients lost 62% of their excess weight, on average, or over 19% of their total body weight.

  • The shorts are really trying to shake this stock down.

  • (Disclosure: I am a patient at Kaiser Permanente and I can tell you they push weight-control programs over surgical intervention. One has to fight to get treatments that other health plans routinely use. Fisher would catch hell from his Kaiser superiors if he wrote favorably about VBLOC. The fact is that intensive lifestyle programs work only for a small minority. Curbing hunger is what VBLOC does. LOL: In Citrus Heights, CA there is a gourmet bakery next to a Weight Watchers meeting. The bakery knows that diet-plan backsliders are some of their best customers: guilt promotes comfort eating).

    David P. Fisher, M.D., of the Permanente Medical Group, Richmond, Calif., wrote in an accompanying editorial that several conclusions can be drawn from this study.
    "First, vagal nerve blockade plus moderately intensive lifestyle counseling does not appear to be much more effective than an intensive lifestyle program. "

0.1432-0.0068(-4.53%)Oct 1 3:22 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Enbridge Inc.
NYSEWed, Oct 1, 2014 4:01 PM EDT
Vivint Solar, Inc.
NYSEWed, Oct 1, 2014 4:00 PM EDT
Angie's List, Inc.
NasdaqGSWed, Oct 1, 2014 4:00 PM EDT